(Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer [unable to retrieve full-text content] Purpose: Resistance to treatment with endocrine therapy in patients with HR+, HER2− advanced breast cancer (ABC) is common and dual inhibition …Published at Tue, 13 Oct 2020 03:05:18 +0000
Read More
Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China Updated : October 13, 2020 10:59 AM IST Alembic Pharma said Curon obtains the exclusive development and commercialisation rights of Tenalisib for Greater China across all oncology indications. Alembic Pharmaceuticals, through its wholly-owned subsidiary, holds 50 percent ownership in Rhizen. […]
Read More Next Generation Immune Checkpoint Inhibitors and Stimulators Market is estimated to be worth … Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions Roots Analysis is pleased to announce the publication of its recent study, […]
Read More
Breast cancer awareness should not stop for a pandemic News With falling screening rates and concerns of a wave of post-COVID diagnoses, further preventive health incentives have been put in place. Almost 73,000 fewer mammograms were performed in April 2020 compared to 2018. Since being plunged into a pandemic, Australia has seen a decrease in […]
Read More
Study examines cancer’s effects on young women’s employment and finances Cancer and its treatment can impact an individual’s ability to work, and employment disruptions can lead to financial hardships. A new study indicates that women who were diagnosed with cancer as adolescents or young adults can be especially vulnerable to these effects. The findings are […]
Read More
One drink a day raises risk of alcohol-linked cancers by 10pc There is low community awareness about the link between most of these cancers and alcohol, says Dr Peter Sarich, a post-doctoral research fellow at Cancer Council NSW, who led the study. There is an urgent need to raise awareness of the link between cancer […]
Read More
Expert Reviews New Diagnostic and Staging Criteria in Multiple Myeloma Due to a dramatic paradigm shift in multiple myeloma, the diagnostic and staging criteria have been updated, which represents the considerable impact the latest developments in the field have made on the management of this disease. In 2014, the International Myeloma Working Group (IMWG) published […]
Read More
Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients The multiple myeloma treatment paradigm has seen an assortment of therapeutic advances in recent years with agents that have demonstrated the ability to extend survival in patients and improving disease outcomes. However, the severity of the disease continues to linger without a cure, calling […]
Read More
MorphoSys AG – Consensus Indicates Potential 49.6% Upside MorphoSys AG with ticker code (MOR) now have 1 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 43.23 and 43.23 with the average target price sitting at 43.23. Given that the […]
Read More
Treatments for Early Stage Plasma Cell Disorders Plasma cell disorders like multiple myeloma, plasmacytoma, smoldering myeloma, MGUS are diseases in which the body makes too many plasma cells. These disorders have different symptoms, treatments, and prognoses. The myeloma panel is talking to Dr. Craig Hofmeister from Winship Cancer Institute on advances in treatments for early […]
Read More